...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer epidemiology >Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients
【24h】

Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients

机译：microRNA-200b的表达降低是神经胶质瘤患者的独立不利预后因素

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and aim: As a member of the microRNA (miR)-200 family, miR-200b has been recognized as one of the fundamental regulators of epithelial-mesenchymal transition, chemosensitivity, cell proliferation, and cell cycle. Especially in glioma, miR-200b targets the CREB1 gene and suppresses the tumor cell growth in vitro. However, its involvement in human glioma has not yet been determined. The aim of this study was to investigate the clinical significance of miR-200b expression in this disease. Methods: miR-200b expression in 266 pairs of human gliomas and matched nonneoplastic brain tissues was measured by real-time quantitative RT-PCR assay. Results: Compared with nonneoplastic brain tissues, the expression level of miR-200b was significantly decreased in glioma tissues (tumor vs. normal: 2.87. ±. 2.05 vs. 8.78. ±. 2.50, P<. 0.001). Of 266 patients with gliomas, 166 (62.41%) were in low miR-200b expression group. In addition, we found that the glioma tissues from high-grade tumors (grade III and IV) had much lower miR-200b expression than glioma tissues from low grade tumors (grade I and II). Moreover, the expression level of miR-200b was positively correlated with Karnofsky performance status (KPS) scores of glioma tissues. The results of a 60-month follow-up in 266 glioma patients further demonstrated that lower miR-200b expression was correlated with worse progression-free survival and overall survival in the patients with grade III and IV gliomas. Both univariate and multivariate analyses revealed that miR-200b was an independent prognostic indicator for glioma. Conclusion: These findings prove that the decreased expression of miR-200b may be associated with malignant tumor progression and poor prognosis in patients with gliomas, suggesting the potential role of miR-200b in glioma management. miR-200b may be a novel and valuable signature for predicting the clinical outcome of patients with gliomas.
机译：背景与目的：作为microRNA（miR）-200家族的成员，miR-200b被公认为是上皮-间质转化，化学敏感性，细胞增殖和细胞周期的基本调节剂之一。特别是在神经胶质瘤中，miR-200b靶向CREB1基因并在体外抑制肿瘤细胞的生长。但是，其与人类神经胶质瘤的关系尚未确定。这项研究的目的是调查这种疾病中miR-200b表达的临床意义。方法：采用实时定量RT-PCR技术检测miR-200b在266对人脑胶质瘤和相匹配的非肿瘤性脑组织中的表达。结果：与非肿瘤性脑组织相比，miR-200b在神经胶质瘤组织中的表达水平显着降低（肿瘤与正常：2.87±2.05与8.78±2.50，P <0.001）。在266例神经胶质瘤患者中，有166例（62.41％）处于低miR-200b表达组。此外，我们发现，来自高等级肿瘤（III和IV级）的神经胶质瘤组织的miR-200b表达要比来自低等级肿瘤（I和II级）的神经胶质瘤组织低得多。此外，miR-200b的表达水平与神经胶质瘤组织的卡氏性能状态（KPS）评分呈正相关。对266名神经胶质瘤患者进行了为期60个月的随访，结果进一步表明，miR-200b表达降低与III级和IV级神经胶质瘤患者的无进展生存期和总体生存期较差有关。单因素和多因素分析均显示miR-200b是神经胶质瘤的独立预后指标。结论：这些发现证明，miR-200b的表达降低可能与胶质瘤患者的恶性肿瘤进展和不良预后有关，提示miR-200b在胶质瘤管理中的潜在作用。 miR-200b可能是预测神经胶质瘤患者临床结局的新颖且有价值的标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号